Quantcast
Home > Quotes > IMGN
IMGN

ImmunoGen, Inc. Common Stock (IMGN) Quote & Summary Data

$5.04
*  
0.14
2.7%
Get IMGN Alerts
*Delayed - data as of Dec. 18, 2018 15:55 ET  -  Find a broker to begin trading IMGN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IMGN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.04 / $ 5.05
1 Year Target
14
Today's High / Low
$ 5.27 / $ 4.90
Share Volume
1,897,736
50 Day Avg. Daily Volume
2,557,819
Previous Close
$ 5.18
52 Week High / Low
$ 13.41 / $ 5.02
Market Cap
751,417,481
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.04
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.77

Intraday Chart

Shares Traded

Share Volume:
1,897,736
50 Day Avg. Daily Volume:
2,557,819

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.04

Trading Range

The current last sale of $5.04 is 0.40% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.27 $ 13.41
 Low: $ 4.90 $ 5.02

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company focused on developing innovative antibody-drug conjugate, or ADC, therapies that meaningfully improve the lives of people with cancer. An ADC with our proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of our potent anti-cancer agents as a "payload" to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with four approved products and the number of agents in development growing significantly in recent years. We have established a leadership position in ADCs. Our proprietary portfolio is led by mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, or FR?.  ... More ...  


Risk Grade

Where does IMGN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.25
Open Date:
Dec. 18, 2018
Close Price:
$ 5.18
Close Date:
Dec. 17, 2018

Consensus Recommendation

Analyst Info